Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/MARINUS PHARMACEUTICALS, INC./ EFFECT

SEC Filing · EFFECT

MARINUS PHARMACEUTICALS, INC.

SEC Filing

Filed Feb 13, 2025Accepted Feb 13, 2025, 7:15 PM ESTCIK 1267813Accession 9999999995-25-000436
View company →Permanent SEC source ↗
Share

Company context

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. Marinus’ product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the United States in 2022. For more information, please visit www.marinuspharma.com and follow us on Facebook, LinkedIn and X.

Recent company filings

  1. SCHEDULE 13G/A - filed by Beryl Capital Management LLC regarding MARINUS PHARMACEUTICALS, INC.May 15, 2025
  2. SCHEDULE 13G/A - filed by MORGAN STANLEY regarding MARINUS PHARMACEUTICALS, INC.Mar 6, 2025
  3. 15-12G filingFeb 21, 2025
  4. SCHEDULE 13G/A - filed by Panacea Innovation Ltd regarding MARINUS PHARMACEUTICALS, INC.Feb 14, 2025
  5. SCHEDULE 13G/A - filed by TANG CAPITAL PARTNERS LP regarding MARINUS PHARMACEUTICALS, INC.Feb 14, 2025

As-filed source

Primary evidence
As filedOpen full document ↗